Tradestie Institutional Equity Comparison Engine

XERS vs NUVB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XERS Overall Edge

XERS Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xeris Biopharma Holdings, Inc. Common Stock (XERS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, XERS trades at 63.6x Forward P/E with 12.7% operating margin (+44.2% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, XERS sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XERS
XERS 63.6x vs NUVB N/M Fwd P/E
Growth & Margin Winner XERS
Op Margin 12.7% vs -61.2% ยท YoY +44.2% vs +242.6%
Momentum & Technical Winner XERS
1Y +139.3% vs -46.9% ยท 52W Pos 97% vs 2%
Options & Structure Winner XERS
SURGE (12th %ile IV) vs BREAKDOWN (26th %ile IV)
XERS NASDAQ
Xeris Biopharma Holdings, Inc. Common Stock
Pharmaceutical Preparations
$16.97
+2.11% 1D
Market Cap $3.0B
1M Return +56.26%
1Y Return +139.35%
Forward P/E 63.6x
Unified AI Score
35.7 / 100 SELL
Tech 50.0 Fund 34.0 Flow 71.0 Mom 40.0
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XERS +139.35% NUVB -46.85% Spread: +186.2 pp (XERS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period XERS Revenue NUVB Revenue XERS Op. Margin NUVB Op. Margin Margin Edge
FY2020 $20M N/A -414.5% N/A XERS
FY2021 $50M N/A -232.2% N/A XERS
FY2022 $110M N/A -74.3% N/A XERS
FY2023 $160M N/A -26.8% N/A XERS
FY2024 $200M $10M -16.6% -7527.3% XERS
FY2025 $290M $60M 8.5% -338.7% XERS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XERS (7) vs NUVB (3)
Institutional Metric XERS NUVB Criterion Row Winner
Market Capitalization Scale $3.0B $1.3B Larger Scale XERS
Trailing P/E Ratio Valuation 87.0x N/M Lower Multiple XERS
Forward P/E Ratio Valuation 63.6x N/M Lower Multiple XERS
Revenue Growth (YoY) Growth +44.2% +242.6% Higher Growth NUVB
Operating Margin (TTM) Profitability 12.7% -61.2% Higher Margin XERS
Net Profit Margin Profitability -1.8% -67.4% Higher Margin XERS
Return on Equity (ROE) Capital Efficiency -27.1% -49.1% Higher ROE XERS
52-Week Range Position Momentum 97% ($5โ€“$17) 2% ($4โ€“$10) Stronger Trend XERS
Beta / 30D Volatility Risk Regime -0.04ฮฒ ยท 104% Vol 1.52ฮฒ ยท 55% Vol Lower Realized Risk NUVB
Unified Institutional Score Composite Signal 35.7 / 100 (SELL) 61.0 / 100 (BUY) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XERS vs NUVB Buy Guide
XERS SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live XERS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XERS nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.